Sciclone Pharmaceut (SCLN) 10.88 $SCLN Sciclone

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sciclone Pharmaceut (SCLN) 10.88 $SCLN

Sciclone Pharmaceuticals Has Returned 70.9% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Fri Jun 10, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 70.93% as of today's recent price of $13.63.
SCLN: 10.88 (+0.32)

Shares of SCLN Up 74.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:11AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 74.17% as of today's recent price of $13.89.
SCLN: 10.88 (+0.32)

Sciclone Pharmaceuticals Shares Up 62.9% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Thu May 26, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 62.88% as of today's recent price of $12.99.
SCLN: 10.88 (+0.32)

AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 57.05 (+0.08), SCMP: 11.89 (+0.14), SCLN: 10.88 (+0.32), BIOD: 0.41 (-0.03)

Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 64.4% (SCLN)
Comtex SmarTrend(R) - Wed May 11, 12:42PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 6 months, Sciclone Pharmaceuticals has returned 64.39% as of today's recent price of $13.11.
SCLN: 10.88 (+0.32)

SciClone Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016.
SCLN: 10.88 (+0.32)

SciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016
PR Newswire - Mon Apr 25, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET (5:30 am PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
SCLN: 10.88 (+0.32)

Shares of SCLN Up 62.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 19, 12:15AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 62.51% as of today's recent price of $12.96.
SCLN: 10.88 (+0.32)

Sciclone Pharmaceuticals Shares Up 55.3% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Mon Apr 11, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 55.30% as of today's recent price of $12.39.
SCLN: 10.88 (+0.32)

Shares of SCLN Up 37.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 01, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 37.62% as of today's recent price of $10.98.
SCLN: 10.88 (+0.32)

Look for Shares of Sciclone Pharmaceuticals to Potentially Pullback after Yesterday's 13.34% Rise
Comtex SmarTrend(R) - Thu Mar 31, 3:35PM CDT
Sciclone Pharmaceuticals (NASDAQ:SCLN) traded in a range yesterday that spanned from a low of $10.35 to a high of $10.99. Yesterday, the shares gained 13.3%, which took the trading range above the 3-day high of $9.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SCLN: 10.88 (+0.32)

WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Wed Mar 30, 5:24PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, April 1:
WBMD: 60.91 (-0.10), TMO: 159.56 (+0.72), SUNE: 0.34 (unch), SCLN: 10.88 (+0.32), MHFI: 107.92 (+1.16), AFFX: 14.01 (+0.02)

SciClone To Present At Needham Healthcare Conference On April 13, 2016
PR Newswire - Wed Mar 30, 5:00AM CDT
FOSTER CITY, Calif., March 30, 2016 /PRNewswire/-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 15th Annual Needham Healthcare Conference at 8:00 am ET on Wednesday, April 13, 2016, at the Westin Grand Central Hotel in New York City.
SCLN: 10.88 (+0.32)

OxySure Therapeutics (OXYS) May Be Undervalued Compared to Others in Biotech Space
ACCESSWIRE - Mon Mar 21, 8:01AM CDT
REDONDO BEACH, CA / ACCESSWIRE / March 21, 2016 / OxySure Therapeutics Inc. (OTCQB: OXYS), developer of oxygen-from-powder technology and related medical solutions, has come a long way over the past year. Management anticipates reaching a $10 million annual run rate and achieving breakeven later this year. With 14 consecutive quarters of revenue growth, the company has a long track record of increasing shareholder value.
SRDX: 27.06 (-0.37), CFMS: 6.92 (-0.05), GKOS: 33.93 (-1.03), BEAT: 19.19 (+0.17), SCLN: 10.88 (+0.32)

SciClone Reports 2015 Financial Results
PR Newswire - Thu Mar 10, 3:05PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter and year ended December 31, 2015.
SCLN: 10.88 (+0.32)

LifeSci Capital Initiates Coverage of SciClone
ACCESSWIRE - Tue Mar 08, 1:45PM CST
Profitable Specialty Pharmaceutical Company with Steady Revenue Growth; Report Available here: http://www.lifescicapital.com/equity-research/sciclone/
BAX: 48.50 (+0.48), PFE: 37.31 (+0.42), SCLN: 10.88 (+0.32)

27.3% Return Seen to Date on SmarTrend Sciclone Pharmaceuticals Call (SCLN)
Comtex SmarTrend(R) - Mon Mar 07, 5:13PM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 4 months, Sciclone Pharmaceuticals has returned 27.27% as of today's recent price of $10.15.
SCLN: 10.88 (+0.32)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 147

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 114

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 102

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 179

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 38

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 237

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 60

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading

Top 5 Most Recently Viewed Articles

B. Riley Financial Partners with Oaktree to Enhance Services

Updated Category News Views 55

B. Riley Financial and Oaktree: A Strategic Collaboration B. Riley Financial, Inc. (NASDAQ: RILY) is thrilled to announce a new partnership with Oaktree Capital Management, L.P. to strengthen its Great American Group businesses. Definitive Agreement Signed The companies have finalized a definitive agreement enabling a collaboration through a newly formed holding company...

Continue Reading
General Motors Faces Changes: A Shift in EV Incentive Strategy

Updated Category News Views 348

General Motors Adjusts EV Incentives General Motors Co. (NYSE: GM) has decided to revise its plans concerning electric vehicle (EV) incentives after initially suggesting options beyond the Federal EV Credit deadline. This shift comes shortly after rising scrutiny from political figures around the implications of such financial strategies. Concerns Raised by Key...

Continue Reading
Pacsun Unveils Stylish New Sunglasses Collection for All

Updated Category News Views 327

Pacsun Launches an Elegant Sunglass Collection Pacsun has taken a bold step in expanding its product range by introducing a new collection of premium sunglasses. This unisex line represents the brand's commitment to elevating its accessory offerings, appealing to a broader audience of style-conscious consumers. Innovative Designs in Sunglass Fashion With the release of...

Continue Reading
Exploring the Rapid Growth of the Opioid Use Disorder Market

Updated Category News Views 216

Understanding the Opioid Use Disorder Market and Its Promising Growth The opioid crisis represents a major public health challenge, significantly impacting communities across the globe. According to research, the Opioid Use Disorder Market was evaluated at approximately USD 3.7 billion recently, with an exciting projection to surge to USD 9.02 billion by 2032. This...

Continue Reading
Artea Bankas Secures ECB Approval for Stock Buyback Initiative

Updated Category News Views 242

Artea Bankas Secures ECB Approval for Stock Buyback Initiative AB Artea Bankas has recently gained essential approval from the European Central Bank (ECB) allowing the bank to buy back up to 4,500,000 of its own shares, marking a significant step in enhancing shareholder value. This buyback program is anticipated to commence within one year, demonstrating the bank's...

Continue Reading